Saturday, October 16, 2021
HomeLatest Pharma-NewsSandoz completes acquisition of GSK’s cephalosporin antibiotics business

Sandoz completes acquisition of GSK’s cephalosporin antibiotics business

October 11, 2021: “Sandoz, a Novartis division, has successfully completed the acquisition of GSK’s cephalosporin antibiotics business.

Through this transaction, Sandoz has acquired rights to three established brands (Zinnat, Zinacef and Fortum)) in more than 100 markets, further reinforcing its leading global position in antibiotics.

- Advertisement -

In 2020, the three brands had combined sales of approximately USD 140 million in the relevant markets.

“Antibiotics are the backbone of modern healthcare systems and a central pillar of our worldwide Sandoz patient offering”, said Sandoz CEO Richard Saynor.

“The successful and timely closing of this important transaction is further proof of our commitment at Sandoz to be a leading global supplier of these essential medicines.

“Cephalosporins are the largest antibiotic segment by global sales and this acquisition complements our #1 position in generic penicillins, the other key segment. It also sets us up for additional synergies driven by an increased promotional footprint across markets.”

The transaction excludes rights to certain brands previously divested by GSK in the US, Australia and Germany. GSK will also retain full brand rights in China (excluding Taiwan, Hong Kong and Macau), India, Pakistan, and Egypt and to certain brands in Japan.

In line with its integrated manufacturing strategy, Sandoz intends in the longer term to manufacture Zinnat at sites in its own network, which has global antibiotics production centered on its lead production site in Kundl, Austria.

In May, Sandoz announced plans to invest more than EUR 150 million in its uniquely vertically-integrated, European-based antibiotics network.”

https://www.novartis.com/news/media-releases/sandoz-completes-acquisition-gsks-cephalosporin-business-reinforcing-leading-global-position-antibiotics

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular